Cannabinoids, Specific Immunoglobulin. Palvizumab 50 mg, 100mg. VIAL(PWDR) + DILUENT: 1 X 50 mg+ 4 ml
diluent, 100 mg + 10 ml diluent.
15 mg/kg by I.M. inject. 1 x mthly
during course of RSV season. See lit.
Preven. of serious lower resp. tract dis.
requir. hospitalis. caused by RSV in child.
at high risk for RSV dis.:
Child. born at 35 wks. of gestation or less
and less than 6 mths. of age at the onset
of the RSV season. Child. less than 2 yrs. of age and requir.
tmt. for bronchopulm. dysplasia within
the last 6 mths.
Children less than 2 yrs. of age and with
haemodyn. signif.congen. heart dis.
C/I: Hypersens. to palvizumab or any
compon. of formula, or other humanized
Antibiotics. Amphotericin B 5mg/ml. VIAL (Concent. for susp.for infus.):
10×20ml. IV infus. at 5 mg/kg at a rate of
2.5 mg/kg/hr. See lit.
Tmt. of sev. invas. candidiasis. As 2nd line
therapy for the tmt. of sev. syst. fungal
infec. in pts. who have not responded to
conventional amphotericin B or other
syst. antifung. agents, in those who have
renal impair. or other contra-indic. to
conventional amphotericin B, or in pts.
who have developed amphotericin B
As 2nd line tmt. for invas. aspergillosis,
cryptococcal meningitis and
disseminated cryptococcosis in HIV pts.,
fusariosis, coccidiomycosis, zygomycosis
Atypical Antipsychotic. Aripiprazole (as monohydrate) 300 mg, 400 mg. PRE-FILLED SYR. (pwdr. + solvent for prolong. -release susp.):1,3. Recom. init. & mainten. dose: 400 mg. once mnthly. as a single inj. (no sooner than 26 d after the previous inj.). After the 1st inj., tmt. with 10 mg- 20 mg oral aripiprazole should be cont. for 14 consec. days to maintain therapeutic aripiprazole concentr. during init. of ther. See lit.
Maintenan. tmt. of schizophrenia in adult pts. stabilised with oral aripiprazole.
Anti-Androgen. Abiraterone Acetate 250 mg. TABS.: 120.
Intended for male pts. only. 1,000 mg (4×250mg tabs.) once dly. in comb. with prednisone.
Indicated in comb. with prednisone for the tmt. of pts. with metastat. castration-resist. prostate cancer.
C/I: Hypersensitivity to active substance or any of its excipients. Use in female patients. Severe hepatic impairment.
NSAID. Diclofenac Sodium 50 mg, 100 mg. SUPPS: 10. 2 supps. at night.
Rheumat. arthr., osteoarthr., low back pain,
other acute musculosk. disord. such as
periarthr., tendin., tenosynov., bursitis,
sprains, strains, dislocation, ankyl.
spondylitis, acute gout. Control of pain/
inflamm. in orthopedic, dental, and other
C/I: Hypersens. to the product. Active
gastr./ intest. ulcer, bleeding or perfor.
Active/ history of recur. peptic ulcer/
haemorrhage (>=2 distinct epis. of
proven ulcer./ bleeding). History of GI
bleeding/perfor., relating to prev. NSAID
tmt. Last trimester of pregn. Sev. hepatic
and renal failure. Establ. CHF (NYHA class
II-IV), isch. heart dis., periph. arter. dis.,
cerebrovasc. dis. Pts. in whom aspirin or
other NSAIDs have induc. sympt. of
asthma, acute rhinitis precipit. by
ibuprofen, urticaria, nasal polyps,
angioedema, bronchospasm, other
sympt. of allergic react. (anaphyl. react.
have occur. in such pts). Pts with sev.
heart failure. Tmt of peri-operative pain
in CABG surg.
S.R. TABS: 20. 1 tab. dly.
Rheum. arthrit., other rheum. conds.